INTRODUCTION
Integrins are present in nearly all multicellular organisms and play a conserved role in mediating cell adhesion to fixed extracellular ligands and in the maintenance of tissue integrity (1) . In invertebrates, a surprisingly small number of integrin heterodimers mediate these diverse functions (2, 3) . Much has been learned about the critical in vivo functions of most members of the integrin family through the use of mice with global or conditional inactivating mutations of individual subunits (4, 5) and through the use of heterodimer-specific blocking monoclonal antibodies (6, 7) . One major exception is the a v b 1 integrin. This integrin, first identified biochemically more than two decades ago (8) , is composed of a and b subunits that are both present in multiple heterodimers (5 in the case of a v and 12 in the case of b 1 ) (1), which has made it difficult to generate heterodimer-specific antibodies or to infer function from gene knockout studies. As a result, this integrin has been largely ignored.
We and others have shown that two members of the integrin family, a v b 6 and a v b 8 , have as their principal ligands latency-associated peptides (LAPs) of the growth factors TGFb1-3 (transforming growth factor-b1-3) (9) (10) (11) and that these integrins play major roles in activation of latent forms of this growth factor that are stored in the extracellular matrix in most healthy adult tissues. In mice, inactivation of both of these integrins recapitulates all of the developmental phenotypes of loss of TGFb1 and TGFb3 (12) . Inhibitors of each of these integrins have identified important and distinct roles for each in multiple disease models and have provided new options for therapeutically targeting TGFb in specific contexts, thereby avoiding potentially undesirable side effects of globally inhibiting this pleiotropic growth factor (9, (13) (14) (15) (16) .
However, in contrast to development, it is clear that there are a number of important pathologic circumstances in adults where inhibition of TGFb is therapeutically effective, but inhibition of a v b 6 and a v b 8 is not. One of these is hepatic fibrosis (17) . We recently used cremediated deletion of the integrin a v subunit in activated fibroblasts to demonstrate that loss of all a v integrins from these cells protects mice from fibrosis in multiple organs, including the liver, and that this effect was associated with reduced tissue TGFb signaling (17) . Tissue fibroblasts can express four a v -containing integrins, a v b 1 , a v b 3 , a v b 5 , and a v b 8 . We found that individual deletion of a v b 3 , a v b 5 , or a v b 8 integrin either globally or conditionally in activated fibroblasts (in the case of a v b 8 integrin) had no effect on organ fibrosis but were unable to examine any possible contributions of the a v b 1 integrin because of the lack of suitable experimental tools. Our previous results could thus have been explained either by redundancy of a v integrins (the interpretation we favored) or by a specific role for fibroblast a v b 1 in driving fibrosis.
To begin to identify important functions for the a v b 1 integrin, we used information from the solved crystal structure of other a v and b 1 integrins (18, 19) and from the design of other small-molecule inhibitors targeting integrins (20) , to develop a potent and specific smallmolecule inhibitor of the a v b 1 integrin. We then used this inhibitor to demonstrate a previously unknown role for this integrin in activating the growth factor TGFb and in driving tissue fibrosis in the lung and liver. through addition of a sulfonamidoproline moiety we had previously shown to bind to the b 1 subunit in a 2 b 1 integrin (Fig. 1A , blue shading), which occupies a hydrophobic pocket in the b 1 chain (20) .
Because cocrystal structures are available for the ligand-binding regions of the a v b 3 and a 5 b 1 integrins (18, 19), we were able to construct a computational model of the a v b 1 integrin to further guide our inhibitor design (Fig. 1C) . We then synthesized a small set of compounds, including the a v -binding base compound and the b 1 -binding sulfonamidoproline moiety separated by amide linkers of various lengths, and found outstanding geometric and electrostatic complementarity when these were docked to our model of the a v b 1 integrin. Potency and specificity of each compound were tested by performing cell adhesion assays with a panel of cell lines and ligands designed to isolate adhesion mediated by individual integrin heterodimers (Fig. 1D, fig. S1 , and table S1). The most promising compound, c8 (Fig. 1B) , is one of two compounds predicted to have the highest affinity based on its excellent fit to the modeled integrin structure. Indeed, c8 inhibited a v b 1 integrinmediated cell adhesion to the previously identified ligand fibronectin (8) , with a sub-nanomolar median inhibitory concentration (IC 50 ), but only minimally inhibited binding mediated by other related integrins up to concentrations five orders of magnitude higher ( Fig. 1E and table S1). A related compound, c6, performed similarly well in binding assays ( fig. S2 ). The remarkable specificity obtained for c8 and c6 demonstrated the effectiveness of our chimeric design strategy and provided us with novel reagents to examine a v b 1 integrin function.
Identification of widespread expression of the a v b 1 integrin on fibroblasts and a critical role for this integrin in activation of latent TGFb by these cells To determine the functional relevance of the a v b 1 integrin, we began by examining its possible role in the process of tissue fibrosis (12) . Fibrosis is a critical contributor to many chronic diseases that eventually lead to organ failure. Despite the societal burden of fibrotic diseases, there are currently few approved therapies. As we reported for hepatic stellate cells, primary murine lung fibroblasts and human fetal and adult lung fibroblasts, as well as lung fibroblasts from patients with idiopathic pulmonary fibrosis (IPF), all clearly expressed the a v b 1 integrin as determined by immunoprecipitation (IP) of a v , followed by Western blotting for b 1 ( Fig. 2A and fig. S5 ). In contrast, whereas both the a v and b 1 subunits were easily detectible in primary endothelial and epithelial cells, coimmunoprecipitation did not detect the a v b 1 heterodimer in these cells.
We and others have reported that the closely related a v integrins a v b 6 (9) and a v b 8 (11) can each bind to an N-terminal fragment of the TGFb1 and TGFb3 gene products called the LAP, which normally forms a noncovalent complex with the active cytokine, preventing TGFb from binding to its receptors and inducing biological effects. When mechanical force is applied to the latent complex by contraction of integrin-expressing cells, the resultant conformational change leads to release of active TGFb1 (21) . Our previous work suggested that an a v integrin on fibroblasts contributed to tissue fibrosis by binding to and activating TGFb (17) . To determine whether the relevant fibroblast integrin could be a v b 1 , we performed cell adhesion assays with either S3 ). We used a coculture system to quantitatively assess TGFb activation (22) and found that c8 potently and specifically inhibited activation of TGFb by CHO cells engineered to express the a v b 1 integrin and by a variety of primary murine and human lung fibroblasts, including fibroblasts from the lungs of patients with IPF, and murine hepatic stellate cells ( Fig. 2D and table S4 ). The IC 50 for c8-mediated inhibition of TGFb activation by these cells ranged from 0.35 to 0.50 nM, close to the IC 50 of 0.75 nM for inhibition of WI38 cell adhesion to LAP (Fig.  2C ). Together, these data suggest that a v b 1 is the principal integrin on fibroblasts responsible for adhesion to TGFb1 LAP and for activation of latent TGFb. A biochemical association between the a v b 1 integrin and TGFb1 LAP was previously reported on the basis of affinity chromatography (23) , but this is the first evidence that contractile cells can use this integrin to activate TGFb.
In vivo role of the a v b 1 integrin in liver and lung fibrosis Having established that c8 inhibits fibroblast adhesion to TGFb1 LAP and TGFb activation by fibroblasts from multiple organs, we used this inhibitor to examine the role of a v b 1 integrin-mediated TGFb activation in two widely used models of pathologic tissue fibrosis: carbon tetrachloride (CCl 4 )-induced hepatic fibrosis and bleomycin-induced pulmonary fibrosis. To determine whether a v b 1 might be a promising therapeutic target, we waited until fibrosis was established in each model (21 days for CCl 4 and 14 days for bleomycin) and then began continuous subcutaneous administration of either c8 or an inactive control compound, c16. In each model, c8 caused a substantial and significant reduction in fibrosis, as measured by either total area of collagen staining or total organ hydroxyproline content (a measure of crosslinked collagen) (Fig. 3 , A to F, and tables S5 and S6). These results are highly comparable to the protection we previously reported in mice with conditional deletion of all a v integrins from activated fibroblasts (17) , suggesting that a v b 1 was probably the major a v integrin responsible for that effect.
Likewise, phosphorylated Smad3 (pSmad3) fluorescence intensity mapping revealed significant down-regulation of canonical (Smadmediated) TGFb signaling (Fig. 4) , suggesting that antifibrotic effects of c8 are due to inhibition of a v b 1 integrin-mediated TGFb activation in vivo. 
Fig 
DISCUSSION
Here, we used a structure-based design to generate the first highly potent and specific inhibitor of the a v b 1 integrin. Our results demonstrating a difference of more than five orders of magnitude between concentrations of this inhibitor required to inhibit a v b 1 compared to six other integrins that all recognize ligands containing the same arginine-glycine-aspartic acid tripeptide suggest that this reagent is highly selective and should be broadly useful in identifying specific functional roles for a v b 1 in vitro and in vivo. Our finding that a v b 1 is the major integrin on several different primary fibroblasts responsible for binding to TGFb1 LAP and for mediating activation of latent TGFb by these cells clarifies several previous reports of integrinmediated TGFb activation by contractile fibroblasts (17, 24) . Our findings that this a v b 1 -specific small-molecule inhibitor results in the same degree of reversal of liver and lung fibrosis as we previously reported for deletion of all a v integrins from fibroblasts provide the first convincing evidence that the a v b 1 integrin is the major integrin on pathologic has been difficult to determine in the absence of effective and specific inhibitors. a v b 1 has thus been alternately described as a receptor for vitronectin (25) , fibronectin (8) , and the adenovirus penton base (26) . One previous study used affinity chromatography of surface-labeled lysates of A549 cells passed over a column composed of recombinant TGFb1 LAP cross-linked to Sepharose beads and found that a v b 1 could bind to TGFb1 LAP, but despite performing coculture TGFb activity bioassays like the one we used here, the authors could not demonstrate evidence of TGFb activation (23) . Recent work overexpressing integrin subunits and latent TGFb in 293 cells also did not demonstrate evidence of TGFb activation by a v b 1 (27) . To try to understand the apparent differences between our results and these previous reports, we performed cell adhesion assays and coculture TGFb bioassays with A549 and 293 cells using the same methods and reagents we used to study CHO cells and fibroblasts ( fig.  S4 ). We confirmed that A549 cells adhere well to TGFb1 LAP and also found evidence of TGFb activation. Both effects were potently inhibited by concentrations of c8 as low as 1 nM. However, despite confirming that 293 cells express a v b 1 , we did not find meaningful adhesion to TGFb1 LAP or TGFb activation by these cells. Future studies examining why 293 cells are incapable of activating TGFb using this integrin could provide insight into additional mechanisms of regulation of integrin-mediated TGFb activation.
An important limitation of the current study is that we did not definitively prove that inhibition of TGFb activation is the only mechanism by which inhibition of a v b 1 decreases the magnitude of tissue fibrosis. Although our data suggest that TGFb activation is one important function of a v b 1 , it certainly remains possible that other as yet unidentified functions of this integrin also have important effects on tissue fibrosis. The mechanisms that regulate formation and surface expression of the a v b 1 heterodimer also need to be identified, because both a v and b 1 monomers are expressed in nearly every cell, but only a minority of cells ever express the a v b 1 heterodimer on their surface. Finally, our finding that 293 cells can express a v b 1 but are incapable of either binding to TGFb1 LAP or activating latent TGFb suggests that there are additional positive and/or negative regulators of the interaction between a v b 1 and TGFb that remain to be identified.
The significant therapeutic effect of our small-molecule a v b 1 integrin inhibitor in two different models of fibrotic disease suggest that this integrin could be a promising target for treatment of the multiple chronic diseases characterized by excessive tissue fibrosis. c8 also should be a useful tool to identify additional roles for this understudied member of the integrin family in modulating cell behavior and in vivo biology.
MATERIALS AND METHODS

Study design
The overall goals of this study were to develop and characterize a smallmolecule inhibitor of the a v b 1 integrin and to assess the possibility that this integrin might be a reasonable therapeutic target for fibrotic diseases affecting multiple organs. To assess the potency and specificity of the candidate inhibitors that we developed, we used in vitro cell adhesion assays and TGFb activation assays. All in vitro experiments were done at least three times with at least triplicate samples.
To evaluate the potential efficacy of our lead small-molecule c8 in vivo, we compared the effects of c8 to those of the inactive peptide analog c16 in mice treated either with vehicle alone or with the fibrogenic stimuli bleomycin (for induction of pulmonary fibrosis) or CCl 4 (for induction of liver fibrosis). Sample size was selected on the basis of extensive experience with each model to allow us to reliably detect a 50% reduction in the magnitude of fibrosis. Treatments were all delivered by continuous subcutaneous infusion beginning at a time point at which we and others had previously demonstrated that fibrosis was already present. Mice were randomized for inclusion in each of the four treatment arms, and all analyses were performed blind to inciting stimulus and treatment. All surviving mice were included for analysis.
Synthesis of inhibitors
Preparation of (PhSO 2 )Pro-(pNO 2 )Phe-OtBu. Diisopropylethylamine (DIPEA) (1 eq), hydroxybenzotriazole (HOBt) (1 eq), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC•HCl) (1 eq) were added to benzenesulfonylproline (40 mmol) in anhydrous dichloromethane (DCM) (100 ml) at 0°C, and the solution was stirred for 1 min. Then, nitrophenylalanine t-butylester in DCM (300 ml) was added at the same temperature and warmed to room temperature (rt) and stirred overnight. The reaction mixture was washed with 1 N hydrochloric acid (HCl), 10% sodium bicarbonate (NaHCO 3 ), and brine successively. The volatiles were removed under reduced pressure, and the crude product was used without further purification (yellowish foam, 70% 
. Preparation of (PhSO 2 )Pro-(pNH 2 )Phe-OtBu. A slurry of Pd/C (palladium on carbon) (0.1 eq based on weight) in MeOH (methanol)/ H 2 O (1:1, 10 ml) and ammonium formate (9 eq) were added to a solution of the above nitrobenzene (27.9 mmol) in MeOH/THF (tetrahydrofuran) (1:1, 300 ml) at rt. The mixture was heated at 60°C for 3 hours and cooled to rt. The mixture was filtered through a pad of Celite and concentrated. The crude residue was dissolved in ethyl acetate and washed with saturated NaHCO 3 solution, dried over sodium sulfate (Na 2 SO 4 ), and concentrated under reduced pressure. The crude product was used without further purification (off-white foam, 70%). 
. Preparation of (PhSO 2 )Pro-(pNHCOCH 2 CH 2 CH 2 CH 2 NHC= NBocNHBoc)Phe-OtBu. DIPEA (1 eq), HOBt (1 eq), and EDC•HCl (1 eq) were added to the bis-Boc-protected aminopentanoic acid (11.2 mmol) (28) in anhydrous DCM (80 ml) at 0°C, and then the amine from the previous step (1 eq) in DCM (20 ml) was added at the same temperature, warmed to rt, and stirred overnight. The reaction mixture was washed with 1 N HCl, 10% NaHCO 3 , and brine successively. The solvent was removed under reduced pressure and purified by silica gel column chromatography (DCM/MeOH, 2% to 5%) to give the off-white foam (74%).
Preparation of c8. The bis-Boc-protected compound prepared from the previous step (8.3 mmol) was treated with 5% anisole in trifluoroacetic acid (TFA) (30 ml) for 3 hours at rt. The volatiles were removed under reduced pressure, and the crude product was washed with diethyl ether several times. The TFA salt was exchanged to chloride using 4 M HCl in dioxane and evaporation under reduced pressure (three times). The final salt was passed through a short pad of silica and dried under reduced pressure. 
Mice
Wild-type C57BL/6 mice were purchased from Jackson Laboratories. Eight-to 12-week-old sex-matched mice were housed under specific pathogen-free conditions in the Animal Barrier Facility of the University of California, San Francisco (UCSF). All experiments were approved by the Institutional Animal Care and Use Committee of the UCSF.
Fibrosis models
Lung and liver fibrosis were induced as described previously (17) . In all studies, mice were randomly assigned for each treatment and analyzed in a blinded fashion. For CCl 4 -induced liver fibrosis, mice were injected intraperitoneally with sterile CCl 4 (1 ml/g body weight) in a 1:3 ratio with olive oil or olive oil (sham), twice weekly for 6 weeks.
Alzet osmotic pumps (Durect) were inserted after 3 weeks of treatment to deliver either c8 or the inactive control small-molecule c16, each dissolved in 50% DMSO (in sterile water) and administered at a dose of 70 mg/kg per day. Livers were harvested 24 hours after the last CCl 4 injection. For bleomycin-induced lung fibrosis, bleomycin (3 U/kg) (Bleo) or water (control) was administered by direct airway intubation with a microsprayer (Penn-Century Inc.). Alzet osmotic pumps were inserted 14 days after treatment as above, and lungs were harvested at 28 days.
Primary cell isolation
Primary murine lung fibroblasts were isolated from 4-to 12-day-old mice using a previously reported method with minor modifications (29) . Mouse lungs were removed, pooled together, and digested in an enzyme solution [Hanks' balanced salt solution (without Ca or Mg) with type I collagenase (0.3 mg/ml) (Sigma) and trypsin (0.5 mg/ml) (Sigma)] for 1 hour with removal of dispersed cells every 10 min. Dispersed cells were passed through a sterile filter (70 mm) into Dulbecco's modified Eagle's medium (DMEM)-Ham's F-12 medium (Sigma) and 10% fetal bovine serum, and undigested lung tissue was placed in fresh enzyme solution. Once digestion was complete, erythrocytes were lysed at rt for 10 min using red blood cell lysing buffer (Sigma). Cells were pelleted by centrifugation and cultured in DMEM with 10% fetal bovine serum and 1% penicillin/streptomycin. Nonadherent cells were aspirated and discarded. Primary murine hepatic stellate cells were isolated and passaged as described previously (17) . Mouse liver was perfused through the inferior vena cava sequentially with liver perfusion medium (Invitrogen), 0.3% pronase (Roche), and 0.02% collagenase (Sigma). The liver was excised and minced with scissors and further digested in 0.044% pronase and 0.008% deoxyribonuclease (DNase) (Roche). The cell suspension was shaken (200 to 250 rpm) at 37°C for 10 min and strained through a sterile filter (70 mm). To remove hepatocytes, the cell suspension was centrifuged at 90g for 2 min, the supernatant was collected, and DNase was added; this procedure was repeated twice. The supernatant was centrifuged at 700g for 7 min to collect the nonparenchymal cell fraction. Collected cells were resuspended in 10 ml of complete DMEM with 10% fetal bovine serum and 1% penicillin/ streptomycin and allowed to differentiate in culture into myofibroblasts before use.
Hydroxyproline assay
Mouse lung and liver tissues were homogenized with trichloroacetic acid and incubated overnight at 110°C in HCl. Samples were reconstituted in water, and hydroxyproline content was measured using the chloramine T assay (30) .
IP and Western blotting
Cells were lysed in radioimmunoprecipitation assay buffer [50 mM trisHCl (pH 7.4), 10 mM MgCl 2 , 125 mM NaCl, and 2% NP-40]. Cell lysates were centrifuged at 14,000 rpm for 10 min at 4°C, and the supernatant was collected. Anti-a v antibody (20 mg) was added to the supernatant, and this was rotated at 4°C for 2 hours, followed by the addition of 30 ml of prewashed protein G-Sepharose slurry (GE Healthcare) for 1 hour at 4°C. The beads were washed three times with phosphatebuffered saline (PBS)/protease inhibitor mixture and once with PBS only. Laemmli sample buffer was added, the samples were boiled for 5 min followed by SDS-polyacrylamide gel electrophoresis, and Western blotting was performed. The antibodies that we used for a v IP were RMV-7 for murine cell lines and L230 for all other cell lines. For a v Western blotting, we used 611012 (1:500) (BD Biosciences), and for b 1 Western blotting, we used 04-1109 (1:500) (Millipore).
TGFb activation assay
Test cells were plated at 50,000 cells per well in 96-well plates together with mink lung epithelial cells expressing firefly luciferase downstream of the TGFb-sensitive portion of the plasminogen activator inhibitor 1 promoter (15,000 to 25,000 cells per well) (22) . Cells were cocultured for 16 hours, and TGFb activity was calculated by measurement of luminescence in the presence and absence of TGFb-blocking antibody 1D11.
Integrin-specific adhesion assays
The effects of c8 and c16 on cell adhesion mediated by a 5 b 1 , a 8 b 1 ,  a v b 1 , a v b 3 , a v b 5 , a v b 6 , and a v b 8 were measured using pairs of cell lines and ligands selected to isolate the effect of each individual integrin. For a 5 b 1 , we used the colon carcinoma cell line SW480 plated on fibronectin (0.3 mg/ml); for a 8 b 1 , we used SW480 cells transfected with human a 8 adhering to recombinant human TGFb1 LAP (1 mg/ml) (31); for a v b 1 , we used CHO a v (a 5 -deficient CHO cells engineered to express a v b 1 ) adhering to fibronectin (0.3 mg/ml) (8); for a v b 3 , we used SW480 cells transfected with human b 3 adhering to fibrinogen (1 mg/ml); for a v b 5 , we used wild-type SW480 cells adhering to vitronectin (0.1 mg/ml); for a v b 6 , we used SW480 cells transfected with human b 6 adhering to recombinant human TGFb1 LAP (0.01 mg/ml); and for a v b 8 , we used the glioma cell line (SNB19) adhering to recombinant human TGFb1 LAP (1 mg/ml). In every case, we confirmed that adhesion could be inhibited by blocking antibodies to the relevant integrin (complex-specific blocking antibodies in all cases except a v b 1 for which we showed equivalent effects of blocking a v ). Cells were resuspended in DMEM for 15 to 30 min at 4°C with 10-fold dilutions of c8 with a starting concentration of 10 mM. Each sample was then added to triplicate wells of a 96-well plate that had been coated overnight at 4°C with the relevant ligand, washed with PBS, blocked by 1-hour incubation with 1% bovine serum albumin (BSA), and washed again. Cells were allowed to attach for 60 min at 37°C. After incubation, nonadherent cells were removed by discarding the medium and spinning the plate topside down at 500 rpm for 5 min. Cells were then fixed and stained with 40 ml of 0.5% crystal violet, 1% formaldehyde, 20% MeOH in double-distilled water for 30 min and lysed with 40 ml of 2% Triton-X in PBS. Absorbance was measured at 595 nm in a microplate reader. For all assays, concentration-response curves were constructed by nonlinear regression analysis, and IC 50 values were calculated using GraphPad Prism software.
Tissue staining
Paraffin-embedded sections were processed as described previously (17) . Sections (5 mm) were stained with hematoxylin and eosin or with Sirius red. Pictures were taken from random fields from each section at a final magnification of ×10. Staining area was calculated by pixel counting with National Institutes of Health (NIH) ImageJ. For fluorescence microscopy, fixed livers and lungs were transferred to 30% sucrose in PBS overnight, embedded in optimum cutting temperature compound, and then cryosectioned at 5 mm. Cryosections were permeabilized and blocked with 0.3% Triton X-100 and 3% BSA in PBS. Sections were incubated with primary antibodies (rabbit anti-pSmad3, Epitomics, 1880-1, 1:100; rat anti-PDGFRb, eBioscience, 14-1402, 1:100) overnight at 4°C and then with fluorophore-conjugated secondary antibodies (Invitrogen). Confocal imaging was performed on a Zeiss LSM 5 Pascal microscope. pSmad immunofluorescence staining was quantified as described (32) .
Statistical analysis
All results are presented as means ± SEM. Exact P values were calculated using the unpaired Student's t test for normally distributed data using GraphPad Prism 6.0. P values and n numbers are shown in the figure legends.
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